PrognomiQ is a biotechnology firm that develops test products to detect early disease detection through the power of multi-omics data.
PrognomiQ has raised $11.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2026.
PrognomiQ's investors include Catalio Capital Management, Wing Venture Capital, Fidelity, Maverick Ventures, Invus.
PrognomiQ is headquartered in San Mateo, United States.
PrognomiQ is a biotechnology firm that develops test products to detect early disease detection through the power of multi-omics data.
PrognomiQ is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PrognomiQ — Funding & Investors." VCBacked, January 16, 2026, https://www.vcbacked.co/company/prognomiq. Accessed September 29, 2026.
VCBacked. (2026). PrognomiQ — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/prognomiq
{{cite web |title=PrognomiQ — Funding & Investors |url=https://www.vcbacked.co/company/prognomiq |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated